Clearside Biomedical (CLSD) Competitors $0.50 -0.04 (-7.72%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$0.50 0.00 (-0.04%) As of 07/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLSD vs. GNLX, MCRB, PLX, SKYE, ONCY, FTLF, TARA, HURA, BHST, and ACTUShould you be buying Clearside Biomedical stock or one of its competitors? The main competitors of Clearside Biomedical include Genelux (GNLX), Seres Therapeutics (MCRB), Protalix BioTherapeutics (PLX), Skye Bioscience (SKYE), Oncolytics Biotech (ONCY), FitLife Brands (FTLF), Protara Therapeutics (TARA), TuHURA Biosciences (HURA), BioHarvest Sciences (BHST), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry. Clearside Biomedical vs. Its Competitors Genelux Seres Therapeutics Protalix BioTherapeutics Skye Bioscience Oncolytics Biotech FitLife Brands Protara Therapeutics TuHURA Biosciences BioHarvest Sciences Actuate Therapeutics Genelux (NASDAQ:GNLX) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations. Is GNLX or CLSD more profitable? Genelux has a net margin of 0.00% compared to Clearside Biomedical's net margin of -818.57%. Clearside Biomedical's return on equity of 0.00% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -93.04% -74.17% Clearside Biomedical -818.57%N/A -114.23% Does the media favor GNLX or CLSD? In the previous week, Clearside Biomedical had 5 more articles in the media than Genelux. MarketBeat recorded 7 mentions for Clearside Biomedical and 2 mentions for Genelux. Genelux's average media sentiment score of 0.94 beat Clearside Biomedical's score of 0.18 indicating that Genelux is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clearside Biomedical 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings and valuation, GNLX or CLSD? Genelux has higher earnings, but lower revenue than Clearside Biomedical. Genelux is trading at a lower price-to-earnings ratio than Clearside Biomedical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$10K12,611.84-$29.87M-$0.88-3.80Clearside Biomedical$1.66M23.28-$34.35M-$0.41-1.21 Do analysts rate GNLX or CLSD? Genelux currently has a consensus target price of $17.75, suggesting a potential upside of 431.44%. Clearside Biomedical has a consensus target price of $4.20, suggesting a potential upside of 744.73%. Given Clearside Biomedical's higher probable upside, analysts plainly believe Clearside Biomedical is more favorable than Genelux.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Clearside Biomedical 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17 Which has more risk and volatility, GNLX or CLSD? Genelux has a beta of -0.34, suggesting that its share price is 134% less volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Do institutionals & insiders believe in GNLX or CLSD? 37.3% of Genelux shares are held by institutional investors. Comparatively, 18.8% of Clearside Biomedical shares are held by institutional investors. 9.3% of Genelux shares are held by insiders. Comparatively, 6.2% of Clearside Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryGenelux beats Clearside Biomedical on 10 of the 17 factors compared between the two stocks. Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLSD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLSD vs. The Competition Export to ExcelMetricClearside BiomedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.87M$3.06B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-1.2121.1828.1020.05Price / Sales23.28288.50432.4490.07Price / CashN/A42.7636.2258.56Price / Book-0.978.378.665.87Net Income-$34.35M-$55.19M$3.25B$258.55M7 Day Performance21.27%5.88%4.23%3.74%1 Month Performance-38.69%17.33%10.52%11.75%1 Year Performance-57.50%4.42%34.41%18.03% Clearside Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLSDClearside Biomedical2.0443 of 5 stars$0.50-7.7%$4.20+744.7%-56.0%$41.87M$1.66M-1.2130GNLXGenelux1.2346 of 5 stars$3.51+5.4%$17.75+405.7%+74.0%$125.74M$10K-3.9910Analyst ForecastMCRBSeres Therapeutics3.5129 of 5 stars$13.85-1.6%$73.67+431.9%-46.6%$122.86M$126.32M-3.01330Positive NewsPLXProtalix BioTherapeutics2.9323 of 5 stars$1.52+4.8%$15.00+886.8%+31.3%$121.00M$59.76M-11.69200SKYESkye Bioscience2.4213 of 5 stars$3.73-4.1%$16.60+345.0%-33.7%$120.49MN/A-4.5511News CoverageONCYOncolytics Biotech1.6634 of 5 stars$1.21-4.7%$4.33+258.1%+1.0%$119.74MN/A-4.1730News CoverageUpcoming EarningsFTLFFitLife Brands4.0839 of 5 stars$12.97+1.8%$20.50+58.1%-23.6%$119.64M$64.47M15.4420News CoverageTARAProtara Therapeutics2.1594 of 5 stars$3.42+11.0%$20.50+499.4%+45.4%$118.83MN/A-1.9930Positive NewsHURATuHURA Biosciences1.7846 of 5 stars$2.55-2.7%$12.67+396.7%N/A$114.44MN/A0.00N/ABHSTBioHarvest SciencesN/A$6.84-1.2%$13.67+99.8%N/A$113.66M$25.19M-13.68N/ANews CoverageACTUActuate Therapeutics2.252 of 5 stars$5.66-1.7%$20.50+262.2%N/A$113.01MN/A0.0010News Coverage Related Companies and Tools Related Companies Genelux Competitors Seres Therapeutics Competitors Protalix BioTherapeutics Competitors Skye Bioscience Competitors Oncolytics Biotech Competitors FitLife Brands Competitors Protara Therapeutics Competitors TuHURA Biosciences Competitors BioHarvest Sciences Competitors Actuate Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLSD) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
